> top > docs > PubMed:9006344 > annotations

PubMed:9006344 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 12-34 SO:0001786 denotes loss of heterozygosity
T2 38-48 GO:0005694 denotes chromosome
T3 38-48 SO:0000340 denotes chromosome
T4 58-85 D002285 denotes atypical ductal hyperplasia
T5 58-85 D002285 denotes atypical ductal hyperplasia
T8 98-107 D002277 denotes carcinoma
T9 98-107 D002277 denotes carcinoma
T10 115-121 UBERON:0000310 denotes breast
T11 186-192 UBERON:0000310 denotes breast
T12 186-202 D001943 denotes breast carcinoma
T13 186-202 D001943 denotes breast carcinoma
T17 204-208 CVCL_5552 denotes DCIS
T16 204-208 D002285 denotes DCIS
T18 204-208 D002285 denotes DCIS
T19 213-223 GO:0005694 denotes chromosome
T20 213-223 SO:0000340 denotes chromosome
T22 312-316 CVCL_5552 denotes DCIS
T21 312-316 D002285 denotes DCIS
T23 312-316 D002285 denotes DCIS
T24 329-334 D009369 denotes tumor
T25 329-334 D009369 denotes tumor
T26 362-384 SO:0001786 denotes loss of heterozygosity
T27 386-389 SO:0001786 denotes LOH
T28 401-405 PR:P00489 denotes PYGM
T29 401-405 PR:000013522 denotes PYGM
T30 401-405 PR:P09812 denotes PYGM
T31 401-405 PR:P11217 denotes PYGM
T32 401-405 PR:Q9WUB3 denotes PYGM
T38 407-412 PR:000007494 denotes INT-2
T39 407-412 Q80UK8 denotes INT-2
T40 407-412 PR:Q9C757 denotes INT-2
T41 407-412 PR:P11487 denotes INT-2
T42 407-412 PR:P05524 denotes INT-2
T43 407-412 P36386 denotes INT-2
T44 407-412 Q9H0H0 denotes INT-2
T45 407-412 PR:000009069 denotes INT-2
T46 407-412 Q5ZKU4 denotes INT-2
T47 417-444 D002285 denotes atypical ductal hyperplasia
T48 417-444 D002285 denotes atypical ductal hyperplasia
T51 446-449 P0A388 denotes ADH
T52 446-449 PR:P06525 denotes ADH
T53 446-449 Q8NXU1 denotes ADH
T54 446-449 Q6GBM4 denotes ADH
T55 446-449 Q47945 denotes ADH
T56 446-449 P0A389 denotes ADH
T57 446-449 Q5HRD6 denotes ADH
T58 446-449 P28036 denotes ADH
T59 446-449 P42327 denotes ADH
T60 446-449 PR:P00332 denotes ADH
T63 446-449 P81786 denotes ADH
T64 446-449 P18278 denotes ADH
T65 446-449 Q44002 denotes ADH
T66 446-449 Q7A742 denotes ADH
T67 446-449 O05542 denotes ADH
T68 446-449 Q2YSX0 denotes ADH
T69 446-449 Q6GJ63 denotes ADH
T70 446-449 PR:P00334 denotes ADH
T72 446-449 Q24857 denotes ADH
T73 446-449 Q8CQ56 denotes ADH
T74 446-449 Q2FJ31 denotes ADH
T75 446-449 Q2G0G1 denotes ADH
T76 446-449 PR:Q2G0G1 denotes ADH
T78 446-449 Q5HI63 denotes ADH
T79 446-449 Q99W07 denotes ADH
T80 446-449 Q04983 denotes ADH
T61 446-449 CHEBI:34543 denotes ADH
T77 446-449 CHEBI:9937 denotes ADH
T62 446-449 GO:0047636 denotes ADH
T71 446-449 GO:0004022 denotes ADH
T81 493-503 D002277 denotes carcinomas
T82 493-503 D002277 denotes carcinomas
T83 511-517 UBERON:0000310 denotes breast
T84 584-593 D002277 denotes carcinoma
T85 584-593 D002277 denotes carcinoma
T86 614-617 P0A388 denotes ADH
T87 614-617 PR:P06525 denotes ADH
T88 614-617 Q8NXU1 denotes ADH
T89 614-617 Q6GBM4 denotes ADH
T90 614-617 Q47945 denotes ADH
T91 614-617 P0A389 denotes ADH
T92 614-617 Q5HRD6 denotes ADH
T93 614-617 P28036 denotes ADH
T94 614-617 P42327 denotes ADH
T95 614-617 PR:P00332 denotes ADH
T98 614-617 P81786 denotes ADH
T99 614-617 P18278 denotes ADH
T100 614-617 Q44002 denotes ADH
T101 614-617 Q7A742 denotes ADH
T102 614-617 O05542 denotes ADH
T103 614-617 Q2YSX0 denotes ADH
T104 614-617 Q6GJ63 denotes ADH
T105 614-617 PR:P00334 denotes ADH
T107 614-617 Q24857 denotes ADH
T108 614-617 Q8CQ56 denotes ADH
T109 614-617 Q2FJ31 denotes ADH
T110 614-617 Q2G0G1 denotes ADH
T111 614-617 PR:Q2G0G1 denotes ADH
T113 614-617 Q5HI63 denotes ADH
T114 614-617 Q99W07 denotes ADH
T115 614-617 Q04983 denotes ADH
T96 614-617 CHEBI:34543 denotes ADH
T112 614-617 CHEBI:9937 denotes ADH
T97 614-617 GO:0047636 denotes ADH
T106 614-617 GO:0004022 denotes ADH
T116 684-689 D009369 denotes tumor
T117 684-689 D009369 denotes tumor
T120 708-716 7906 denotes paraffin
T118 708-716 D010232 denotes paraffin
T119 708-716 D010232 denotes paraffin
T123 754-757 SO:0000352 denotes DNA
T122 754-757 CHEBI:16991 denotes DNA
T124 754-757 D004247 denotes DNA
T121 754-757 GO:0005574 denotes DNA
T125 787-792 SO:0000419 denotes chain
T126 787-801 MOP:0000635 denotes chain reaction
T127 811-817 D009369 denotes tumors
T128 811-817 D009369 denotes tumors
T130 852-856 CVCL_5552 denotes DCIS
T129 852-856 D002285 denotes DCIS
T131 852-856 D002285 denotes DCIS
T132 858-861 SO:0001786 denotes LOH
T133 914-920 D009369 denotes tumors
T134 914-920 D009369 denotes tumors
T135 947-950 P0A388 denotes ADH
T136 947-950 PR:P06525 denotes ADH
T137 947-950 Q8NXU1 denotes ADH
T138 947-950 Q6GBM4 denotes ADH
T139 947-950 Q47945 denotes ADH
T140 947-950 P0A389 denotes ADH
T141 947-950 Q5HRD6 denotes ADH
T142 947-950 P28036 denotes ADH
T143 947-950 P42327 denotes ADH
T144 947-950 PR:P00332 denotes ADH
T147 947-950 P81786 denotes ADH
T148 947-950 P18278 denotes ADH
T149 947-950 Q44002 denotes ADH
T150 947-950 Q7A742 denotes ADH
T151 947-950 O05542 denotes ADH
T152 947-950 Q2YSX0 denotes ADH
T153 947-950 Q6GJ63 denotes ADH
T154 947-950 PR:P00334 denotes ADH
T156 947-950 Q24857 denotes ADH
T157 947-950 Q8CQ56 denotes ADH
T158 947-950 Q2FJ31 denotes ADH
T159 947-950 Q2G0G1 denotes ADH
T160 947-950 PR:Q2G0G1 denotes ADH
T162 947-950 Q5HI63 denotes ADH
T163 947-950 Q99W07 denotes ADH
T164 947-950 Q04983 denotes ADH
T145 947-950 CHEBI:34543 denotes ADH
T161 947-950 CHEBI:9937 denotes ADH
T146 947-950 GO:0047636 denotes ADH
T155 947-950 GO:0004022 denotes ADH
T165 973-983 D002277 denotes carcinomas
T166 973-983 D002277 denotes carcinomas
T167 985-988 SO:0001786 denotes LOH
T169 1041-1045 CVCL_5552 denotes DCIS
T168 1041-1045 D002285 denotes DCIS
T170 1041-1045 D002285 denotes DCIS
T171 1053-1057 32644 denotes none
T173 1075-1079 CVCL_5552 denotes DCIS
T172 1075-1079 D002285 denotes DCIS
T174 1075-1079 D002285 denotes DCIS
T175 1111-1114 SO:0001786 denotes LOH
T178 1174-1178 CVCL_5552 denotes DCIS
T177 1174-1178 D002285 denotes DCIS
T179 1174-1178 D002285 denotes DCIS
T181 1254-1258 CVCL_5552 denotes DCIS
T180 1254-1258 D002285 denotes DCIS
T182 1254-1258 D002285 denotes DCIS
T183 1272-1277 D009369 denotes tumor
T184 1272-1277 D009369 denotes tumor
T185 1279-1282 SO:0001786 denotes LOH
T186 1335-1341 D009369 denotes tumors
T187 1335-1341 D009369 denotes tumors
T188 1346-1349 P0A388 denotes ADH
T189 1346-1349 PR:P06525 denotes ADH
T190 1346-1349 Q8NXU1 denotes ADH
T191 1346-1349 Q6GBM4 denotes ADH
T192 1346-1349 Q47945 denotes ADH
T193 1346-1349 P0A389 denotes ADH
T194 1346-1349 Q5HRD6 denotes ADH
T195 1346-1349 P28036 denotes ADH
T196 1346-1349 P42327 denotes ADH
T197 1346-1349 PR:P00332 denotes ADH
T200 1346-1349 P81786 denotes ADH
T201 1346-1349 P18278 denotes ADH
T202 1346-1349 Q44002 denotes ADH
T203 1346-1349 Q7A742 denotes ADH
T204 1346-1349 O05542 denotes ADH
T205 1346-1349 Q2YSX0 denotes ADH
T206 1346-1349 Q6GJ63 denotes ADH
T207 1346-1349 PR:P00334 denotes ADH
T209 1346-1349 Q24857 denotes ADH
T210 1346-1349 Q8CQ56 denotes ADH
T211 1346-1349 Q2FJ31 denotes ADH
T212 1346-1349 Q2G0G1 denotes ADH
T213 1346-1349 PR:Q2G0G1 denotes ADH
T215 1346-1349 Q5HI63 denotes ADH
T216 1346-1349 Q99W07 denotes ADH
T217 1346-1349 Q04983 denotes ADH
T198 1346-1349 CHEBI:34543 denotes ADH
T214 1346-1349 CHEBI:9937 denotes ADH
T199 1346-1349 GO:0047636 denotes ADH
T208 1346-1349 GO:0004022 denotes ADH
T218 1378-1383 D009369 denotes tumor
T219 1378-1383 D009369 denotes tumor
T220 1378-1394 GO:0051726 denotes tumor suppressor
T221 1378-1394 GO:0008181 denotes tumor suppressor
T222 1395-1399 SO:0000704 denotes gene
T224 1414-1424 SO:0000340 denotes chromosome
T223 1414-1424 GO:0005694 denotes chromosome
T225 1454-1464 SO:1000009 denotes transition
T226 1510-1516 UBERON:0000310 denotes breast
T227 1510-1523 D001943 denotes breast cancer
T228 1510-1523 D001943 denotes breast cancer

DisGeNET

Id Subject Object Predicate Lexical cue
T0 401-405 gene:5837 denotes PYGM
T1 417-444 disease:C1332347 denotes atypical ductal hyperplasia
T2 401-405 gene:5837 denotes PYGM
T3 493-503 disease:C0007097 denotes carcinomas
T4 401-405 gene:5837 denotes PYGM
T5 538-553 disease:C0677898 denotes invasive cancer
T6 407-412 gene:57508 denotes INT-2
T7 417-444 disease:C1332347 denotes atypical ductal hyperplasia
T8 407-412 gene:2248 denotes INT-2
T9 417-444 disease:C1332347 denotes atypical ductal hyperplasia
T10 407-412 gene:57508 denotes INT-2
T11 446-449 disease:C1332347 denotes ADH
T12 407-412 gene:2248 denotes INT-2
T13 446-449 disease:C1332347 denotes ADH
T14 407-412 gene:57508 denotes INT-2
T15 493-503 disease:C0007097 denotes carcinomas
T16 407-412 gene:2248 denotes INT-2
T17 493-503 disease:C0007097 denotes carcinomas
T18 407-412 gene:57508 denotes INT-2
T19 538-553 disease:C0677898 denotes invasive cancer
T20 407-412 gene:2248 denotes INT-2
T21 538-553 disease:C0677898 denotes invasive cancer
R1 T0 T1 associated_with PYGM,atypical ductal hyperplasia
R2 T2 T3 associated_with PYGM,carcinomas
R3 T4 T5 associated_with PYGM,invasive cancer
R4 T6 T7 associated_with INT-2,atypical ductal hyperplasia
R5 T8 T9 associated_with INT-2,atypical ductal hyperplasia
R6 T10 T11 associated_with INT-2,ADH
R7 T12 T13 associated_with INT-2,ADH
R8 T14 T15 associated_with INT-2,carcinomas
R9 T16 T17 associated_with INT-2,carcinomas
R10 T18 T19 associated_with INT-2,invasive cancer
R11 T20 T21 associated_with INT-2,invasive cancer

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-122 DRI_Background denotes Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast.
T2 123-335 DRI_Background denotes Identical allelic loss in invasive and adjacent in situ ductal breast carcinoma (DCIS) on chromosome 11q13 has been previously reported, providing molecular evidence for the progression of DCIS to invasive tumor.
T3 336-554 DRI_Challenge denotes In this study we analyzed loss of heterozygosity (LOH) on 11q13 (PYGM, INT-2) in atypical ductal hyperplasia (ADH) and various histological types of in situ carcinomas of the breast in patients without invasive cancer.
T4 555-631 DRI_Background denotes Twenty-four cases of in situ carcinoma and twelve cases of ADH were studied.
T5 632-802 DRI_Background denotes Tissue microdissection of normal, hyperplastic, and tumor cells from fixed, paraffin-embedded sections was performed, and DNA was extracted for polymerase chain reaction.
T6 803-857 DRI_Background denotes In situ tumors included both high- and low-grade DCIS.
T7 858-957 DRI_Background denotes LOH was identified in six of twenty-two (27.3%) in situ tumors and in one of eleven (9%) ADH cases.
T8 958-1080 DRI_Background denotes Within in situ carcinomas, LOH was identified in six of seventeen (35%) high-grade DCIS but in none of six low-grade DCIS.
T9 1081-1278 DRI_Challenge denotes The present results show that LOH at 11q13 occurs in an appreciable proportion of high-grade DCIS, although the rate is substantially less than in patients with concomitant DCIS and invasive tumor.
T10 1279-1524 DRI_Background denotes LOH was identified less frequently in low-grade in situ tumors and ADH, suggesting that a putative tumor suppressor gene(s) located on chromosome 11q13 may be involved in the transition from early preneoplastic lesions to invasive breast cancer.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 123-335 DRI_Background denotes Identical allelic loss in invasive and adjacent in situ ductal breast carcinoma (DCIS) on chromosome 11q13 has been previously reported, providing molecular evidence for the progression of DCIS to invasive tumor.
T2 336-554 DRI_Challenge denotes In this study we analyzed loss of heterozygosity (LOH) on 11q13 (PYGM, INT-2) in atypical ductal hyperplasia (ADH) and various histological types of in situ carcinomas of the breast in patients without invasive cancer.
T3 555-631 DRI_Background denotes Twenty-four cases of in situ carcinoma and twelve cases of ADH were studied.
T4 632-802 DRI_Background denotes Tissue microdissection of normal, hyperplastic, and tumor cells from fixed, paraffin-embedded sections was performed, and DNA was extracted for polymerase chain reaction.
T5 803-857 DRI_Background denotes In situ tumors included both high- and low-grade DCIS.
T6 858-957 DRI_Background denotes LOH was identified in six of twenty-two (27.3%) in situ tumors and in one of eleven (9%) ADH cases.
T7 958-1080 DRI_Background denotes Within in situ carcinomas, LOH was identified in six of seventeen (35%) high-grade DCIS but in none of six low-grade DCIS.
T8 1081-1278 DRI_Challenge denotes The present results show that LOH at 11q13 occurs in an appreciable proportion of high-grade DCIS, although the rate is substantially less than in patients with concomitant DCIS and invasive tumor.
T9 1279-1524 DRI_Background denotes LOH was identified less frequently in low-grade in situ tumors and ADH, suggesting that a putative tumor suppressor gene(s) located on chromosome 11q13 may be involved in the transition from early preneoplastic lesions to invasive breast cancer.

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
9006344-2#65#69#gene5837 401-405 gene5837 denotes PYGM
9006344-2#81#108#diseaseC1332347 417-444 diseaseC1332347 denotes atypical ductal hyperplasia
9006344-2#202#217#diseaseC0677898 538-553 diseaseC0677898 denotes invasive cancer
65#69#gene583781#108#diseaseC1332347 9006344-2#65#69#gene5837 9006344-2#81#108#diseaseC1332347 associated_with PYGM,atypical ductal hyperplasia
65#69#gene5837202#217#diseaseC0677898 9006344-2#65#69#gene5837 9006344-2#202#217#diseaseC0677898 associated_with PYGM,invasive cancer